A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing–remitting multiple sclerosis
Mots clés
- NCT02424396
- Neurodegeneration
- Immunotherapy
- Tolerance
- Immunosuppression
- Immunoregulation
- EU Clinical trials Register: 2014-000088-42 Neuroinflammation
- EU Clinical trials Register: 2014-000088-42 Neuroinflammation Neurodegeneration Immunoregulation Immunosuppression Tolerance Immunotherapy
- NCT02424396